Loading stock data…
Bristol-Myers Squibb Company (BMY)
$64.69-2.13 (-3.19%)
Market ClosedLast close Sep 8
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bristol-Myers Squibb Company in the Healthcare sector is trading at $64.69 with a market capitalization of $130.4B. Wall Street consensus targets $66.21 (24 analysts), implying a +2.3% move over the next 12 months. The stock is currently near its 52-week high of $68.64, remaining 12.7% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.97B↑ | $11.49B↓ | $12.50B↑ | $12.22B↓ | $12.27B |
| Gross Profit | $9.25B↑ | $8.07B↓ | $8.41B↓ | $8.79B↓ | $8.90B |
| Operating Income | $4.03B↑ | $3.37B↑ | $2.81B↓ | $3.64B↓ | $3.77B |
| Net Income | $3.32B↑ | $2.68B↑ | $1.09B↓ | $2.20B↑ | $1.31B |
Peer Comparison
JNJUNHPFE
Fundamentals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$130.39B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.88%
ROE
Elite ROE. Management converts capital into profit efficiently.
41.59%
Volume
Today's trading volume
9.45M
Recent News
Is AbbVie Stock Too Reliant On Skyrizi?
AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.
Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends
Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.
What Merck Stopped Saying About GARDASIL Should Change What You Watch
Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.
Social Security’s 2027 COLA Raise Is the Biggest in 3 Years — But These 5 Dividend Stocks Pay You More
Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and some have raised their payouts for decades straight.